Table 1 Demographic and clinical characteristics of EGFR mutation related patients.

From: Non-invasive decision support for NSCLC treatment using PET/CT radiomics

Characteristic

Training cohort (N = 429)

Validation cohort (N = 187)

HMU EGFR-test-cohort (N = 65)

EGFR+

(N = 201)

EGFR−

(N = 228)

P

EGFR+

(N = 75)

EGFR−

(N = 112)

P

EGFR+

(N = 36)

EGFR−

(N = 29)

P

Age(y)

  

0.55

  

0.99

  

0.21

   Mean ± SD

62.79 ± 8.65

63.26 ± 8.94

 

62.6 ± 9.14

62.47 ± 9.32

 

58.81 ± 10.4

61.07 ± 9.07

 

Sex, no. (%)

  

<.001*

  

<.001*

  

.047*

   Female

137 (68.16)

57 (25)

 

50 (66.67)

23 (20.54)

 

24 (66.67)

12 (41.38)

 

   Male

64 (31.84)

171 (75)

 

25 (33.33)

89 (79.46)

 

12 (33.33)

17 (58.62)

 

TNM stage

  

0.23

  

<.001*

  

0.52

   I

116 (57.71)

111 (48.68)

 

47 (62.67)

56 (50)

 

8 (22.22)

7 (24.14)

 

   II

30 (14.93)

47 (20.61)

 

8 (10.67)

24 (21.43)

 

2 (5.56)

1 (3.45)

 

   III

30 (14.93)

42 (18.42)

 

8 (10.67)

20 (17.86)

 

6 (16.67)

9 (31.03)

 

   IV

25 (12.44)

28 (12.28)

 

12 (16)

12 (10.71)

 

20 (55.56)

12 (41.38)

 

Histology (baseline), no. (%)

  

<.001*

  

<.001*

  

.002*

   ADC

197 (98.01)

157 (68.86)

 

75 (100)

80 (71.43)

 

36 (100)

22 (75.86)

 

   SCC

4 (1.99)

71 (31.14)

 

0 (0)

31 (27.68)

 

0 (0)

7 (24.14)

 

Smoking status, no. (%)

  

<.001*

  

0.076

  

.070

   Never

156 (77.61)

80 (35.09)

 

56 (74.67)

36 (32.14)

 

25 (69.44)

13 (44.83)

 

   Former

45 (22.39)

148 (64.91)

 

19 (25.33)

76 (67.86)

 

11 (30.56)

16 (55.17)

 

SUVmax

  

<.001*

  

<.001*

  

0.99

   Mean ± SD

7.92 ± 5.22

10.17 ± 5.7

 

6.97 ± 4.82

10.32 ± 5.52

 

9.47 ± 7.67

8.41 ± 6.06

 

PD-L1 status, no. (%)

  

.069

  

0.28

  

NA

   ≥50%

10 (4.98)

24 (10.53)

 

5 (6.67)

12 (10.71)

 

NA

 

   1–49%

12 (6.97)

30 (13.16)

 

3 (4.00)

12 (10.71)

  

   0%

89 (43.28)

102 (44.74)

 

32 (42.67)

48 (42.86)

  

   Unknown

90 (44.78)

72 (31.58)

 

35 (46.67)

40 (35.71)

  

EGFR-deep learning score (EGFR-DLS)

  

<.001*

  

<.001*

  

<.001*

   Median

(IQR)

0.65

(0.54, 0.73)

0.34

(0.15, 0.34)

 

0.63

(0.55, 0.70)

0.38

(0.21, 0.49)

 

0.55

(0.38, 0.66)

0.26

(0.08, 0.44)

 
  1. The comparison of age, EGFR-DLS, and SUVmax between two groups was performed with two-sided Wikcoxon sign-rank test, and the rest variables were compared with two-sided Fisher’s test. IQR is short for interquartile range. ADC is short for adenocarcinoma and SCC is short for squamous cell carcinoma.
  2. NA not available.
  3. *p Value <0.05.
Back to article page